Navigation Links
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
Date:6/25/2008

BRANFORD, Conn., June 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study.

The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every three weeks to patients with locally-advanced or metastatic breast cancer who have received prior therapy. This study will enroll up to approximately 40 patients to confirm the maximum tolerated dose (MTD) in this population and to assess efficacy using a Simon 2-Stage design with an endpoint of progression-free rate at 12 weeks. The principal investigator is Dr. Linda Vahdat, Medical Director of the Breast Cancer Research Program and Associate Professor of Clinical Medicine, NewYork-Presbyterian Hospital/Weill Cornell.

"We believe that GPNMB is a promising target in breast cancer, and we look forward to better understanding how CR011-vcMMAE could be used in the treatment of this disease," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "We are confident in our ability to continue the rapid development of this program and look forward to providing updated CR011-vcMMAE results for the treatment of melanoma by the end of 2008 and the presentation of preliminary results from this newly initiated study in breast cancer during the first half of 2009."

CR011-vcMMAE targets a protein known as glycoprotein NMB (GPNMB), which is overexpressed in a variety of cancers including breast cancer, melanoma, and brain tumors. CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against GPNMB linked
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Stryker Corporation,s Orthopaedics Division, the Official Joint Replacement Products of ... of joint health to golf fans in its home state ... The Barclays.  The company,s fan destination – "The Stryker Mobility ... 17 th fairway at the Ridgewood Country Club in ... st .    At The Barclays, Stryker will ...
(Date:8/19/2014)... N.Y. , Aug. 19, 2014  Regeneron Pharmaceuticals, ... following investor conferences: , Sanofi and Regeneron will host ... Eastern Time on Tuesday, September 2, 2014 , ... on Wednesday, September 3, 2014 , Citi,s 9 ... Time on Thursday, September 4, 2014 , Morgan ...
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
Breaking Medicine Technology:Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... Oct. 13, 2011 K-V Pharmaceutical Company (the ... of Obstetricians and Gynecologists (ACOG) and Society for ... that ensures healthcare providers, patients, and the payer ... information update emphasizes that previous ACOG and SMFM ...
... 13, 2011 IVD Technology , ... diagnostics technologies including research, development, and manufacturing, today announced ... emerging trend in the industry – ... (CONTACT:   http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ) The featured speaker ...
Cached Medicine Technology:K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8Distinguished Speaker Dr. Elizabeth Mansfield Joins IVD Technology for Upcoming Webcast: The Regulation of Companion Diagnostics: Current Status and Updates 2Distinguished Speaker Dr. Elizabeth Mansfield Joins IVD Technology for Upcoming Webcast: The Regulation of Companion Diagnostics: Current Status and Updates 3
(Date:8/20/2014)... they often have difficulty falling asleep and staying asleep, ... In individuals with Alzheimer,s disease, this common and troubling ... leading to nighttime confusion and wandering. , Now, a ... Center (BIDMC) and the University of Toronto/Sunnybrook Health Sciences ... age. Reported online today in the journal Brain ...
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... will honor the 2014 Emmy Award Nominees and Presenters at ... place on August 22nd and 23rd in Beverly Hills from ... enjoy gifts, refreshments and music by DJ Morgan Hildebrand. , ... charity fundraising and will feature several charities at the lounge. ...
(Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
(Date:8/20/2014)... York (PRWEB) August 20, 2014 Over 31 ... Global Bureau of Disease, low back pain is the single ... most common reasons for missed work. Americans spend at least ... pain. , Most cases of back pain are not due ... (non-organic) origin. , For example, Pete, a busy accountant, had ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 As moms and ... for themselves to return to the normal routine of dropping ... in tow, Kristen Yarker, MSc, RD encourages them to ... their kids’ snack time. , Yarker explains, “Kids have ... nutrients. Instead of giving them junk food handouts, use snack ...
Breaking Medicine News(10 mins):Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... of stroke victims suffer vision difficulties due to cortical ... holds immense promise for patients suffering partial impairment of ... medical instrument has been devised that is capable of ... This could indeed be the light at the end ...
... gene expression in the mouse brain is considered a scientific ... or 57.7 million people//. , ,The Allen Institute ... The Allen Institute was started in 2003 and the Atlas ... given by Microsoft co-founder Paul G. Allen funded both. ...
... Sufferers,Television personality Angela Rippon is fronting a new DVD ... Chronic Obstructive Pulmonary Disease (COPD). The DVD called Move ... ,COPD includes a range of lung diseases like chronic ... make a difference to the lives of people living ...
... HIV/AIDS is a major hindrance in controlling the fast-spreading disease ... discrimination are indeed problem areas in tackling HIV/AIDS in India," ... for HIV/AIDS in Asia and the Pacific. ,"There ... lots needs to be done to make it (the disease) ...
... for the cartoon man, Popeye, who simply preens at the ... spinach and an icon that little kids swear by, what ... who still boasts of a perfect vision without the help ... with a novel eye device are trying to understand the ...
... Drug Administration takes days to track down the source of ... sensor that can enable growers to do the job themselves ... engineering at Drexel University, has developed an “intelligent” sensor technology ... dollars, the sensor can provide a result within 10 minutes ...
Cached Medicine News:Health News:Allen Brain Atlas – a 3-D gene map of brai 2Health News:Remove Stigma to Defeat HIV/AIDS in India, says UN Envoy 2Health News:Go Green with Popeye: Learn why his eyes pop out for spinach! 2
... Implant System provides todays surgeon with ... head replacement. Modular stem and ... while minimizing ligamentous and soft tissue ... guide assists in both the radial ...
... modular radial head system employs the advantages ... to create the next generation of modular ... part, modular design, the implant system offers ... the patients anatomy. In addition, the capability ...
All Padgett bipolar forceps are foot activated. The standard-type connectors fit generators utilizing the standard receivers for small "banana" inserts. All Padgett bipolar foot activated forceps an...
For connection to the bipolar output of electrosurgical generators....
Medicine Products: